-
1 Comment
Nantong Jinghua Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 7.1% above its 200 day moving average.
From a valuation standpoint, the stock is 67.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
Nantong Jinghua Pharmaceutical Co., Ltd's total revenue rose by 46.2% to $318M since the same quarter in the previous year.
Its net income has increased by 98.9% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 1256.4% to $80M since the same quarter in the previous year.
Based on the above factors, Nantong Jinghua Pharmaceutical Co., Ltd gets an overall score of 5/5.
| Industry | Drug Manufacturers-Specialty & Generic |
|---|---|
| Sector | Healthcare |
| ISIN | CNE100000L14 |
| CurrencyCode | CNY |
| Exchange | SHE |
| Market Cap | 9B |
|---|---|
| Target Price | 30.98 |
| PE Ratio | 40.69 |
| Dividend Yield | 0.6% |
| Beta | 0.19 |
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. Jinghua Pharmaceutical Group Co., Ltd. was founded in 1957 and is based in Nantong, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002349.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
